Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral ONC201 in Adult Recurrent Glioblastoma

Next Previous
Trial Profile

Oral ONC201 in Adult Recurrent Glioblastoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dordaviprone (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Chimerix; Oncoceutics

Most Recent Events

  • 09 Sep 2025 According to Jazz Pharmaceuticals plc media release, Modeyso received accelerated approval based on a pre-specified integrated efficacy analysis of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label clinical studies (ONC006, ONC013, ONC014, ONC016 and ONC018). Continued approval may be contingent upon verification and description of clinical benefit in the ongoing Phase 3 ACTION trial.
  • 06 Aug 2025 According to Jazz Pharmaceuticals media release, the company will host a webcast on August 27, 2025, at 4:30 p.m. ET / 9:30 p.m. IST to provide investors an overview of clinical data, patient need and commercialization strategy for Modeyso.
  • 06 Aug 2025 According to Jazz Pharmaceuticals media release, The FDA's accelerated approval decision was based on an integrated efficacy analysis of 50 patients with recurrent H3 K27M-mutant diffuse midline glioma, selected from five open-label clinical studies (ONC006, ONC013, ONC014, ONC016, and ONC018).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top